Combination lomustine and temozolomide for glioblastoma – pro
There is a very small study by Herrlinger in the first line that concludes: ” The findings should be interpreted with caution, owing to the small size of the trial”.
A randomized study, not including TTF< was published in 202, concluding: “Further study will be required to confirm the integrity and generalizability of these findings.”
U. Herrlinger et al, Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA09): a randomised, open-label, phase 3 trial. Lancet VOLUME 393, ISSUE 10172, P678-688, FEBRUARY 16, 2019
Das S, Sahgal A, Perry JR. Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Front Oncol. 2020;10:66. Published 2020 Jan 31. doi:10.3389/fonc.2020.00066